Holen Sie sich die Stockscreener-App
3.58
15.86%
0.49
Schlusskurs vom Vortag:
$3.09
Offen:
$3.5
24-Stunden-Volumen:
5.65M
Relative Volume:
4.92
Marktkapitalisierung:
$153.23M
Einnahmen:
$1.23M
Nettoeinkommen (Verlust:
$-28.62M
KGV:
-2.2805
EPS:
-1.5698
Netto-Cashflow:
$-14.11M
1W Leistung:
+13.65%
1M Leistung:
-13.94%
6M Leistung:
+87.43%
1J Leistung:
+45.53%
1-Tages-Spanne:
$3.3706
$4.1497
1-Wochen-Bereich:
$2.90
$4.1497
52-Wochen-Spanne:
$1.62
$5.055
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Firmenname
Nrx Pharmaceuticals Inc
Sektor
Branche
Telefon
484-254-6134
Adresse
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
3.58 | 155.37M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-02 | Eingeleitet | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Aktie (NRXP) Neueste Nachrichten
NRX Pharmaceuticals Inc (NRXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NRX Pharmaceuticals Market Sentiment - Benzinga España
NRX Pharmaceuticals Inc (NRXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NRX Pharmaceuticals Inc (NRXP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NRX Pharmaceuticals Inc (NRXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NRX Pharmaceuticals Inc (NRXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NRX Pharmaceuticals Inc (NRXP) Cash Flow - TradingKey
NRXP|NRX Pharmaceuticals Inc|Price:3.620|Chg%:-0.130 - TradingKey
TradingKey - TradingKey
NRX Pharmaceuticals, Inc. Revenue Breakdown – MUN:B1Q - TradingView
NRX Pharmaceuticals, Inc. Revenue Breakdown – FWB:B1Q - TradingView
NRX Pharmaceuticals Inc (B1Q.HM) stock price, news, quote and history - Yahoo Finance UK
NRX Pharmaceuticals Inc (B1Q.HM) stock major holders - Yahoo Finance UK
NRX Pharmaceuticals Inc (NRXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NRx Pharmaceuticals Selected by DARPA for Innovative SPARC-TMS Clinical Trial to Treat Depression - Minichart
Market Sentiment Around Loss-Making NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) - Sahm
NRXP Stock Price, Quote & Chart - ChartMill
Is NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation? - Yahoo Finance
NRX Pharmaceuticals Inc (NRXPW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Equity in earnings of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
NRXP Should I Buy - Intellectia AI
First Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell 3000E Growth Benchmark - marketscreener.com
NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Price to book forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to sales forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to sales forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Enterprise value to EBITDA forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Price to earnings forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Enterprise value to EBIT forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Enterprise value to EBIT forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to earnings forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
NRX Pharmaceuticals(NRXP) Stock Options Chain | Quotes & News - Moomoo
H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP) - The Globe and Mail
NRx Pharmaceuticals Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute - The Manila Times
NRX Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:NRXP) - TradingView
NRx Pharmaceuticals responds to Kadima dispute claims - Investing.com UK
NRx Pharmaceuticals responds to Kadima dispute claims By Investing.com - Investing.com South Africa
NRx subsidiary begins AI-guided TMS treatments in Florida - Investing.com UK
NRXP Forecast — Price Target — Prediction for 2027 - TradingView
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System - GlobeNewswire
Kadima sues NRx Pharmaceuticals over failed acquisition deal - Investing.com UK
Kadima Neuropsychiatry Institute Sues NRX Pharmaceuticals Over Breach of Acquisition Contract - marketscreener.com
Kadima sues NRx Pharmaceuticals over failed acquisition deal By Investing.com - Investing.com South Africa
Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition - Business Wire
NRx Pharmaceuticals, Inc. (NRXP) reports Q1 loss, lags revenue estimates - MSN
Finanzdaten der Nrx Pharmaceuticals Inc-Aktie (NRXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):